Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fgf-18 in graft transplantation and tissue engineering procedures

A technology of FGF-18 and tissue engineering, applied in the field of regenerative medicine, can solve the problems such as the speed and quality of cartilage incorporation need to be improved

Active Publication Date: 2016-12-14
MERCK PATENT GMBH
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] While cartilage repair procedures such as osteochondral grafts and cultured cartilage implants (e.g., ACI) are promising, the rate and quality of the resulting cartilage can be improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fgf-18 in graft transplantation and tissue engineering procedures
  • Fgf-18 in graft transplantation and tissue engineering procedures
  • Fgf-18 in graft transplantation and tissue engineering procedures

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] method:

[0077] Fresh hyaline cartilage was collected from the trochlear groove of juvenile achyranthes knees (3-6 months old). An 8 mm cylindrical explant was removed through a biopsy punch ( figure 1 A), and in complete medium (DMEM 4.5g / L D-glucose and L-glutamine, 10% FBS, 1% PSF, 1% amphotericin B (Fungizone), 1% MEM vitamins, 25mM HEPES and 50 μg / ml vitamin C) overnight. Sample bone removal and defect construction (4mm diameter) to form a core ring repair structure ( figure 1 B). The inner core and outer ring were cultured separately for 24 hours, and then the original core was used to fill the defect. Samples were then cultured in complete medium or treated with Sprifermin (rhFGF18, 100 ng / ml). Treatment consisted of administration of rhFGF18 for 24 hours, once a week (and repeated weekly) (1+6), or 24 hours of treatment followed by culture in complete medium for 1 month (1+30 days). Samples were collected after 4 weeks of culture. Using a custom test b...

Embodiment 2

[0084] method:

[0085] Isolation of native osteoarthritic chondrocytes from patients undergoing total joint replacement. Cells were grown in monolayer culture for several days and then in scaffold-free 3D culture for a week before initiating treatment. The treatment consisted of continuous incubation with rhFGF-18 [100 ng / mL] or one day per week for four weeks. The results were compared to a control medium without sprifermin. The three-dimensional structure was characterized using biochemical assays, quantitative PCR (qPCR) and histology.

[0086] Results (data not shown):

[0087] To ensure maintenance of the phenotype, 3D scaffold-free medium was used to test the effect of sprifermin on hOA chondrocytes. In this setting, rhFGF-18 was demonstrated to have a beneficial effect [1 day per week] on cell content and significantly increased the size and matrix content (GAG and HPro content) of 3D structures. It was also found that rhFGF18 reduced collagen I expression compare...

Embodiment 3

[0091] method:

[0092] Porcine chondrocytes were isolated from femoral head cartilage of porcine hip. After joint dissection, cartilage was collected and digested with collagenase 0.25% for 45 min. Loose cells were discarded, and the cartilage was further digested with collagenase 0.1% overnight to extract chondrocytes. Porcine chondrocytes were cultured in suspension as CTA (cartilage tissue analogue) without any treatment for the first week, followed by one of the following treatments: 1) four weeks in medium continuously containing 10 or 100 ng / mL rhFGF18, 2) ) culture medium containing 10 or 100 ng / mL rhFGF18 for one week, followed by culture medium without rhFGF18 for three weeks, 3) medium supplemented with 10 or 100 ng / mL rhFGF18 on 1 day per week (i.e. contact 24 hours, followed by culturing in a medium without rhFGF18 for 6 days) for three weeks, or 4) in a medium without rhFGF18 for four weeks, as a control group ( Figure 4 ). At the end of the culture period, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a new methods related to regenerative medicine for the treatment of cartilage disorders, osteoarthritis and cartilage injury in particular. More particularly, it relates to an FGF-18 compound for use in tissue engineering and graft procedures, such as osteochondral or cartilage transplantation or autologous chondrocyte implantation (ACI)..

Description

technical field [0001] The present invention relates to regenerative medicine, particularly regenerative medicine for the treatment of cartilage diseases such as osteoarthritis, cartilage damage and osteochondral defects. More specifically, the present invention relates to FGF-18 compounds useful in tissue engineering and transplantation procedures such as osteochondral or cartilage transplantation, or autologous chondrocyte transplantation (ACI). Background technique [0002] In general, cartilage disease refers to a disease characterized by the exacerbation of metabolic abnormalities in the connective tissue, manifested by pain, stiffness and limited movement of the affected body part. These diseases can be caused by pathogens (eg, osteoarthritis (OA)) or by trauma or injury. Osteochondral defects (OCD, a defect in the cartilage that covers the ends of bones in joints) are more often caused by trauma or injury, but can also be caused by pathogens. OCD can lead to OA. Ma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61L27/36
CPCA61L27/3654A61L27/3687A61L2300/412A61L2430/06A61L2430/24A61L27/3612A61P19/00C07K14/50C12N5/0655C12N2513/00A61F2/30A61K38/18A61L27/36A61L27/54C12N2501/119
Inventor C·H·雷德尔H·焦耳林A·吉古特
Owner MERCK PATENT GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com